Generation and characterization of monospecific and bispecific hexavalent trimerbodies

mAbs

Volumn 5, Issue 1, 2013, Pages 70-79

  Blanco Toribio, Ana ^a   Sainz Pastor, Noelia ^b   Álvarez Cienfuegos, Ana ^a   Merino, Nekane ^c   Cuesta, Ángel M ^b,f   Sánchez Martín, David ^b,g   Bonet, Jaume ^d   Santos Valle, Patricia ^b   Sanz, Laura ^b   Oliva, Baldo ^d   Blanco, Francisco J ^c,e   Álvarez Vallina, Luis ^b  

^a Leadartis SL   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c CIC BIOGUNE   (Spain)

^d CBB Laboratory   (Spain)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

^f GOETHE UNIVERSITY   (Germany)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody engineering; Bispecific antibodies; Collagen; Multivalent antibodies; Trimerbody

Indexed keywords

CD3 ANTIGEN; LAMININ; MONOCLONAL ANTIBODY; OKT 3; SCAFFOLD PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRIMERBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; MAMMAL CELL; PROTEIN DOMAIN; PROTEIN MULTIMERIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, CD3; COLLAGEN TYPE XVIII; HEK293 CELLS; HUMANS; JURKAT CELLS; LAMININ; LYMPHOCYTE ACTIVATION; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TRANSFECTION;

EID: 84872854587     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22698     Document Type: Article

References (35)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442
2. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641-8; PMID:15916728; http://dx.doi.org/10.1111/j.1745-7254.2005.00135.x
3. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
4. Cuesta AM, Sainz-Pastor N, Bonet J., Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28:355-62; PMID:20447706; http://dx.doi.org/10.1016/j.Tibtech.2010.03.007
5. Holliger P, Hudson PJ Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142
6. Pack P, Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 1992; 31:1579-84; PMID:1737014; http://dx.doi.org/10.1021/bi00121a001
7. Li S-L, Liang S-J, Guo N, Wu A.M., Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49:243-52; PMID:10941907; http://dx.doi.org/10.1007/s002620000115
8. Hu S, Shively L, Raubitschek A., Sherman M, Williams LE, Wong JYC, et al Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56:3055-61; PMID:8674062
9. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
10. Deyev SM, Waibel R, Lebedenko E.N., Schubiger A P, Plückthun A. Design of multivalent complexes using the barnase barstar module. Nat Biotechnol 2003; 21:1486-92; PMID:14634668; http://dx.doi.org/10.1038/nbt916
11. Borsi L, Balza E, Carnemolla B., Sassi F, Castellani P, Berndt A., et al Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102:4384-92; PMID:12933583; http://dx.doi.org/10.1182/blood-2003-04-1039
12. Halin C, Gafner V, Villani M.E., Borsi L., Berndt A, Kosmehl H, et al Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleu-kin 12 and to tumor necrosis factor α. Cancer Res 2003; 63:3202-10; PMID:12810649
13. Cloutier SM, Couty S, Terskikh A., Marguerat L, Crivelli V, Pugnières M, et al Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol Immunol 2000; 37:1067-77; PMID:11399324; http://dx.doi.org/10.1016/S0161-5890(01)00023-2
14. Rossi EA, Goldenberg DM, Cardillo T.M., McBride WJ, Sharkey RM, Chang C-H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006; 103:6841-6; PMID:16636283; http://dx.doi.org/10.1073/pnas.0600982103
15. Sánchez-Arévalo Lobo VJ, Cuesta AM, Sanz L, Compte M, García P, Prieto J, et al. Enhanced anti-angiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006; 119:455-62; PMID:16477626; http://dx.doi.org/10.1002/ijc.21851
16. Cuesta ÁM, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, et al. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS ONE 2009; 4:e5381; PMID:19401768; http://dx.doi.org/10.1371/journal.pone.0005381
17. Cuesta AM, Sánchez-Martín D, Blanco-Toribio A, Villate M, Enciso-Álvarez K, Alvarez-Cienfuegos A, et al. Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs 2012; 4:226-32; PMID:22453098; http://dx.doi.org/10.4161/mabs.4.2.19140
18. Kappler J, Kubo R, Haskins K., White J, Marrack P. The mouse T cell receptor: comparison of MHC-restricted receptors on two T cell hybridomas. Cell 1983; 34:727-37; PMID:6605198; http://dx.doi.org/10.1016/0092-8674(83)90529-9
19. Meuer SC, Hodgdon JC, Hussey R.E., Protentis J P, Schlossman S F, Reinherz EL Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones. J Exp Med 1983; 158:988-93; PMID:6604129; http://dx.doi.org/10.1084/jem.158.3.988
20. Kaye J, Gillis S, Mizel S.B., Shevach EM, Malek TR, Dinarello CA, et al Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol 1984; 133:1339-45; PMID:6235287
21. Santos-Valle P., Guijarro-Muñoz I, Cuesta ÁM, Alonso-Camino V, Villate M, Álvarez-Cienfuegos A, et al. The Heterotrimeric Laminin Coiled-Coil Domain Exerts Anti-Adhesive Effects and Induces a Pro-Invasive Phenotype. PLoS ONE 2012; 7:e39097; http://dx.doi.org/10.1371/journal.pone. 0039097
22. Fan C-Y, Huang C-C, Chiu W-C, Lai C-C, Liou G-G, Li H-C, et al. Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. FASEB J 2008; 22:3795-804; PMID:18635738; http://dx.doi.org/10.1096/fj.08-111484
23. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127; http://dx.doi.org/10. 4161/mabs.1.6.10015
24. Sanz L, Kristensen P, Blanco B., Facteau S, Russell SJ, Winter G, et al Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 2002; 9:1049-53; PMID:12101437; http://dx.doi.org/10.1038/sj.gt.3301725
25. Sanz L, García-Bermejo L, Blanco FJ, Kristensen P, Feijóo M, Suárez E, et al. A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J 2003; 22:1508-17; PMID:12660158; http://dx.doi.org/10.1093/emboj/cdg150
26. Kung P, Goldstein G, Reinherz E.L., Schlossman S F. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206:347-9; PMID:314668; http://dx.doi.org/10.1126/sci-ence.314668
27. Compte M, Blanco B, Serrano F., Cuesta AM, Sanz L, Bernad A, et al Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14:380-8; PMID:17218946; http://dx.doi.org/10.1038/sj.cgt.7701021
28. Alonso-Camino V., Sánchez-Martín D, Compte M, Sanz L, Alvarez-Vallina L. Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS ONE 2009; 4:e7174; PMID:19777065; http://dx.doi.org/10.1371/journal.pone.0007174
29. Fiser A, Sali A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 2003; 374:461-91; PMID:14696385; http://dx.doi.org/10.1016/S0076-6879(03)74020-8
30. Hwang WC, Lin Y, Santelli E., Sui J, Jaroszewski L, Stec B., et al Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006; 281:34610-6; PMID:16954221; http://dx.doi.org/10.1074/jbc.M603275200
31. Berman HM, Westbrook J, Feng Z., Gilliland G, Bhat TN, Weissig H, et al The Protein Data Bank. Nucleic Acids Res 2000; 28:235-42; PMID:10592235; http://dx.doi.org/10.1093/nar/28.1.235
32. Altschul S.F., Madden TL, Schäffer AA, Zhang J., Zhang Z, Miller W, et al Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402; PMID:9254694; http://dx.doi.org/10.1093/nar/25.17.3389
33. Boehm MK, Corper AL, Wan T, Sohi M.K., Sutton BJ, Thornton JD, et al Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 2000; 346:519-28; PMID:10677374; http://dx.doi.org/10.1042/ 0264-6021:3460519
34. Boudko S.P., Sasaki T, Engel J., Lerch T F, Nix J, Chapman M.S., et al Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold. J Mol Biol 2009; 392:787-802; PMID:19631658; http://dx.doi.org/10.1016/j.jmb.2009.07.057
35. Russell RB, Barton GJ Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. Proteins 1992; 14:309-23; PMID:1409577; http://dx.doi.org/10.1002/prot.340140216